phrykt

Viridian Therapeutics, Inc.\DE (VRDN): who owns it and who trades it

As of Nov 16, 2026, VRDN insiders reported 3 open-market sales worth $419K and 1 purchase worth $20M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Tousignant (Chief Legal Officer), with $419K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Viridian Therapeutics, Inc.\DE

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VRDN

215 funds and institutions reported VRDN shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)16.1%
BlackRock, Inc.8.3%
Bellevue Group AG6.5%
Paradigm Biocapital Advisors LP6.5%
Kynam Capital Management, LP6.3%
State Street Corp5.9%
T. Rowe Price Associates5.6%
Fairmount Funds Management LLC4.9%
Vanguard Capital Management LLC4.4%
Deep Track Capital, LP3.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)16.60M16.11%$305M+8%
BlackRock, Inc.8.55M8.30%$157M+9%
Bellevue Group AG6.73M6.53%$124M+0%
Paradigm Biocapital Advisors LP6.72M6.52%$124M+114%
Kynam Capital Management, LP6.45M6.26%$119M+176%
State Street Corp6.12M5.94%$113M+31%
T. Rowe Price Associates5.75M5.58%$106M+79%
Fairmount Funds Management LLC5.09M4.94%$93.5M+30%
Vanguard Capital Management LLC4.58M4.44%$84.1M+10%
Deep Track Capital, LP3.59M3.49%$66M+158%
Venrock Adviser, LLC3.26M3.16%$59.8M-16%
Wellington Management Group LLP3.13M3.04%$57.5M+2%
Vanguard Portfolio Management LLC2.75M2.67%$50.6M+68%
Geode Capital Management, LLC2.50M2.43%$46M+7%
Avoro Capital Advisors LLC2.50M2.43%$45.9M+67%
Baker Bros. Advisors LP2.38M2.31%$43.8M+21%
Point72 Asset Management, L.P.2.34M2.27%$43M+626%
Caligan Partners LP2.19M2.13%$40.3M–
Novo Holdings A/s2.13M2.07%$39.2M+7%
Tang Capital Management LLC1.79M1.74%$32.9MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VRDN insiders reported $20M of open-market purchases and $419K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$20M
1 trades, 1 people
Sales, 12 months
$419K
3 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 19, 2026
Filed Aug 20, 2026

Purchases and sales by month

$20M$20MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 19, 2026Jennifer TousignantChief Legal OfficerSale10,000$24.50$245KForm 4
Aug 19, 2026Jennifer TousignantChief Legal OfficerSale4,212$24.50$103KForm 4
May 11, 2026Fairmount Healthcare Fund II L.P. +2DirectorPurchase1.18M$17.00$20MForm 4
Dec 31, 2025Jennifer TousignantChief Legal OfficerSale2,272$31.16$70.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Fairmount Healthcare Fund II L.P.Director, 10% owner$20M–May 11, 2026
Jennifer TousignantChief Legal Officer–$419KAug 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VRDN short interest

High short interest. 15.0% of VRDN shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 19%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17.04M VRDN shares were sold short, 15.0% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 1.88M shares, buying them all back would take about 9.1 trading days (days to cover).

Shares short, % of all shares

15.0%May 15Oct 3019.4%

Days to cover

9.1May 15Oct 3018.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617.04M15.04%-5%1.88M9.1
Oct 15, 202618.00M15.89%+0%2.24M8.0
Sep 30, 202617.97M15.86%-8%2.03M8.9
Sep 15, 202619.47M17.18%-0%1.24M15.7
Aug 31, 202619.51M17.22%+3%1.18M16.6
Aug 14, 202619.03M16.79%-1%2.10M9.1
Jul 31, 202619.23M18.66%+2%1.70M11.3
Jul 15, 202618.92M18.36%+9%1.92M9.9
Jun 30, 202617.34M16.83%+15%3.12M5.6
Jun 15, 202615.02M14.57%+3%1.49M10.1
May 29, 202614.60M14.16%+2%1.85M7.9
May 15, 202614.27M13.84%+24%4.67M3.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Viridian Therapeutics, Inc.\DE company events

Viridian Therapeutics, Inc.\DE filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementThe Company announced positive results of a phase 1 clinical trial in healthy volunteers of VRDN-008, a half-life extended bifunctional FcRn inhibitor, which the Company believes supports a potential best-in-class FcRn-inhibitor profile with every-eight-week subcutaneous dosing. Filing
  2. Nov 4, 2026ResultsReleased financial results. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 29, 2026AnnouncementThe Company announced that the FDA has approved Lumvoa ™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration. Filing
  5. Jun 3, 2026VoteReported shareholder vote results. Filing
  6. May 28, 2026AgreementEnded an important agreement. Filing
  7. May 26, 2026AgreementViridian Therapeutics, Inc. entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for… Filing
  8. May 11, 2026AgreementViridian Therapeutics, Inc. completed its public offering of $250 million of its 1.75% Convertible Senior Notes due 2032, including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million of the Notes, solely to cover over-allotments. Filing
  9. May 5, 2026AnnouncementShared information with investors. Filing
  10. May 5, 2026ResultsReleased financial results. Filing
  11. Mar 30, 2026AnnouncementShared information with investors. Filing
  12. Feb 26, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Viridian Therapeutics, Inc.\DE financials

Famous investors that hold VRDN

5 of the 50 well-known investors we track reported holding VRDN in their latest 13F filing. The largest position is Steve Cohen's, worth $95.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20264.63M$95.4M0.2%+98%
Ken Griffin · Citadel AdvisorsQ3 20261.88M$38.8M0.0%+4459%
Jim Simons · Renaissance TechnologiesQ3 2026435,700$9M0.0%-43%
Paul Tudor Jones · Tudor Investment CorpQ3 2026103,247$2.1M0.0%+66%
Israel Englander · Millennium ManagementQ3 202613,841$285K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VRDN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.5%
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A7.3%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.5%
Nov 16, 2026Paradigm BioCapital Advisors LP13G/A7.3%
Nov 10, 2026STATE STREET CORPORATION13G4.3%
Nov 10, 2026STATE STREET CORPORATION13G4.3%

Questions about Viridian Therapeutics, Inc.\DE (VRDN) stock

Who owns the most VRDN stock?

The largest reported owner of Viridian Therapeutics, Inc.\DE (VRDN) is FMR LLC (Fidelity), with 16.1% of the company. In total, 215 funds and institutions reported holding VRDN at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are VRDN insiders buying or selling?

In the last 12 months, VRDN insiders reported 1 open-market purchase worth $20M and 3 sales worth $419K. The latest trade was on Aug 19, 2026. See every trade.

What is the short interest in VRDN?

As of Oct 30, 2026, 17.04M VRDN shares were sold short, 15.0% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 1.88M shares, buying them all back would take about 9.1 trading days (days to cover). See the history.

Which famous investors hold VRDN?

5 of the 50 well-known investors we track reported VRDN in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $95.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.